For the quarter ending 2026-03-31, INBX had $37,437K increase in cash & cash equivalents over the period. -$38,026K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -33,441 | -32,834 | -35,256 | -71,965 |
| Depreciation and amortization | 537 | 564 | 583 | 1,336 |
| Accretion of debt discount and non-cash interest expense | 732 | 642 | 638 | 1,159 |
| Stock-based compensation expense | 2,653 | 2,743 | 3,175 | 5,220 |
| Non-cash lease expense | - | 1,803 | - | - |
| Non-cash gain on transaction with acquirer | - | 0 | - | - |
| Loss on disposal of property and equipment | - | -9 | -3 | - |
| Non-cash gain on transaction with acquirer | - | - | 0 | 0 |
| Non-cash lease expense | -851 | - | 456 | 878 |
| Accounts receivable | 0 | 46 | -127 | -119 |
| Other receivables | 9 | -706 | -3 | 689 |
| Receivables from related parties | 0 | 0 | 0 | -23 |
| Prepaid expenses and other current assets | 1,063 | -423 | -25 | -952 |
| Other non-current assets | 0 | 0 | 22 | -22 |
| Accounts payable | 2,818 | -829 | -1,519 | -953 |
| Accrued expenses | -10,187 | -1,434 | -1,515 | -1,412 |
| Operating lease liability | -549 | -535 | -522 | -538 |
| Net cash used in operating activities | -38,026 | -30,122 | -33,824 | -65,848 |
| Purchase of property and equipment | 0 | 0 | 10 | 21 |
| Proceeds from the sale of property and equipment | - | 0 | 3 | - |
| Net cash used in investing activities | 0 | 0 | -7 | -21 |
| Proceeds from the issuance of debt | 74,992 | 0 | 0 | 99,965 |
| Payment of third-party fees associated with debt | - | 125 | - | - |
| Payment of fees associated with debt | -125 | - | 0 | 125 |
| Proceeds from the exercise of stock options | 471 | 1,254 | 352 | 0 |
| Net cash provided by financing activities | 75,463 | 1,254 | 352 | 99,840 |
| Net increase in cash and cash equivalents | 37,437 | -28,868 | -33,479 | 33,971 |
| Cash and cash equivalents at beginning of period | 124,220 | 153,088 | 152,596 | - |
| Cash and cash equivalents at end of period | 161,657 | 124,220 | 153,088 | - |
Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (INBX)